Gossamer Bio, Inc.
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
– New Drug Application for Seralutinib in PAH Submitted to the U.S. FDA in September 2026 –
Company newsroom
Gossamer Bio, Inc.
NASDAQ:GOSS
1 releases